FTC OKs Pfizer-Wyeth merger
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission clears Pfizer's $68 billion acquisition of Wyeth on the condition Pfizer sell half of Wyeth's animal health business to Boehringer Ingelheim Vetmedica. Pfizer announced in September that it would relinquish those assets. FTC noted while the companies' human drug portfolios are highly complementary, they do not raise anticompetitive concerns and consumers will not suffer because of the overlap. The firms also recently passed multiple other merger milestones, including obtaining approvals from the European Commission and stockholders (1"The Tan Sheet" July 27, 2009)
You may also be interested in...
Sales & Earnings In Brief
Schering-Plough consumer sales cool: Schering-Plough's consumer health sales fell 5 percent to $381 million in the firm's fiscal 2009 second quarter "primarily due to lower sales of sun care products due to the unseasonable weather," according to Chief Financial Officer Bob Bertollini. Sun care sales fell 17 percent to $96 million compared to $115 million during the year-ago quarter. Sales of laxative MiraLAX reached $36 million, a 30 percent increase, according to a July 21 earnings statement. The MiraLAX growth helped offset a 10 percent drop of OTCClaritin sales to $108 million in the April-June period, Bertollini said during a same-day earnings call. Schering expects its merger with Merck to close in the fourth quarter (1"The Tan Sheet" March 16, 2009)
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.